Common Stock, $0.0001 par value per share
- Symbol
- NKTX
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 5.07, 9.01 · 8-K
Nkarta, Inc.
NKTXNASDAQEQUITYCurrent
Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. The 2026 annual meeting of stockholders (the "Annual Meeting") of Nkarta, Inc. (the "Company") was held on June 10, 2026. The results of the voting at the Annual Meeting are set forth below. Election of Directors.…
Company context
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for people living with autoimmune diseases. By harnessing the power of the innate immune system to eliminate pathogenic B cells driving the autoimmune response, Nkarta is advancing novel cell therapies engineered for deep therapeutic impact. The on-demand availability and outpatient dosing of our CAR-NK cells enables a broad population of patients with different autoimmune conditions to conveniently access NK cell therapy in community health settings. For more information, please visit the company’s website at www.nkartatx.com.
Current securities
Registered securities in this filing
Nkarta, Inc. · 8-K · Filed 2026-06-11
Disclosure sections
Item 5.07Item 5.07 - Submission of Matters to Vote
Item 5.07 Submission of Matters to a Vote of Security Holders.
The 2026 annual meeting of stockholders (the "Annual Meeting") of Nkarta, Inc. (the "Company") was held on June 10, 2026. The results of the voting at the Annual Meeting are set forth below.
Election of Directors. The stockholders elected the following two Class III directors to serve until the Company’s 2029 annual meeting of stockholders and until their respective successors are duly elected and qualified. The voting results were as follows:
For Withheld Broker Non-Votes
─────────────────────────────────────────────────────────────────────────────────────
Ali Behbahani, M.D., M.B.A. 32,285,680 14,559,531 6,934,994
Zachary Scheiner, Ph. D. 37,313,469 9,531,742 6,934,994
Ratification of Appointment of Ernst & Young LLP. The stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. The voting results were as follows:
For Against Abstain Broker Non-Votes
──────────────────────────────────────────────────────────────
53,684,352 76,073 19,780 —
Advisory Approval of the Compensation Paid to the Company’s Named Executive Officers. The stockholders approved, on a non-
binding, advisory basis, the compensation paid to the Company’s named executive officers. The voting results were as follows:
For Against Abstain Broker Non-Votes
────────────────────────────────────────────────────────────────
43,493,065 3,313,424 38,722 6,934,994
Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation. The stockholders voted, on a non-binding, advisory basis, on the frequency of future advisory votes on the compensation paid to the Company’s named executive officers. The voting results were as follows:
1 Year 2 Years 3 Years Abstain Broker Non-Votes
─────────────────────────────────────────────────────────────────────────────
34,447,256 21,461 4,565,940 354,355 6,934,994
In light of the voting results and consistent with the recommendation of the Company’s Board of Directors, the Company has determined that it will hold future advisory votes on executive compensation every year until the next required advisory vote on the frequency of future advisory votes on executive compensation.